IDO1

Indoleamine 2,3-dioxygenase 1 · P14902 · IDO1 on Sugi Atlas →

372,179 patent compounds predicted against IDO1, 184,483 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL45434	1.00	20/20
Econazole (SCHEMBL34498)	1.00	14/20
Econazole (SCHEMBL34499)	1.00	14/20
Miconazole (SCHEMBL2866)	1.00	12/20
(R)-Miconazole (SCHEMBL2867)	1.00	12/20
Miconazole (SCHEMBL3366)	0.98	12/20
(R)-Miconazole (SCHEMBL3367)	0.98	12/20
Econazole (SCHEMBL36213)	0.84	12/20
Econazole (SCHEMBL36214)	0.84	12/20
Enilconazole (SCHEMBL22498)	1.00	11/20
Miconazole (SCHEMBL15799)	0.84	11/20
(R)-Miconazole (SCHEMBL15800)	0.84	11/20
Tioconazole (SCHEMBL41354)	0.77	11/20
Tioconazole (SCHEMBL41355)	0.77	11/20
SCHEMBL41754	0.58	11/20
Sulconazole (SCHEMBL34761)	1.00	10/20
Sulconazole (SCHEMBL34762)	1.00	10/20
Enilconazole (SCHEMBL41653)	0.88	9/20
SCHEMBL45253	0.50	9/20
SCHEMBL29638	1.00	8/20

Clinical trials — most relevant to IDO1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)	PHASE3	COMPLETED
Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma	PHASE2	UNKNOWN
Safety and Tolerability of IDO-1 Inhibition in the Prevention of EBV-related Pathology in EBV Negative Kidney Transplant Recipients Receiving an Organ From EBV Positive Donors	PHASE2	NOT_YET_RECRUITING
UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma	PHASE1/PHASE2	COMPLETED
Pembrolizumab in Treating Patients With Malignant Mesothelioma	PHASE2	COMPLETED
Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)	PHASE2	COMPLETED
A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors	PHASE1/PHASE2	RECRUITING
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC	PHASE2	COMPLETED
Biomarker Study of PDR001 in Combination With MCS110 in Gastric Cancer	PHASE2	UNKNOWN
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors	PHASE1/PHASE2	RECRUITING
Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma	PHASE1/PHASE2	COMPLETED
Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck	PHASE2	ACTIVE_NOT_RECRUITING
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy	PHASE2	WITHDRAWN
A Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma	PHASE2	WITHDRAWN
Mesenchymal Stem Cells Transplantation to Patients With Relapsed/Refractory Aplastic Anemia.	PHASE1/PHASE2	UNKNOWN
Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer	PHASE2	COMPLETED
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma	PHASE2	COMPLETED
IDO Peptid Vaccination for Stage III-IV Non Small-cell Lung Cancer Patients.	PHASE1	COMPLETED
Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy	PHASE1	UNKNOWN
1-Methyl-D-Tryptophan in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery	PHASE1	COMPLETED
A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients	PHASE1	COMPLETED
Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors	PHASE1	UNKNOWN
Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma	PHASE1	ACTIVE_NOT_RECRUITING
FS2 Safety and Tolerability Study in Healthy Volunteers	PHASE1	COMPLETED
An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment	PHASE1	COMPLETED
Resistance to Immunotherapy in Gastric Cancer	nan	UNKNOWN
TSK (Tryptophan - Serotonin - Kynurenine) Biomarkers Assessment in Stroke	nan	COMPLETED
An Assessment of Cognitive Function in Irritable Bowel Syndrome	nan	UNKNOWN
The Immunomodulatory Effect of Antrifibrinolytic (Tranexamic Acid) in Total Knee Arthroplasty	nan	UNKNOWN
Evaluating a Personalised Online Program With Human Support for Women With Depression and Its Impact on Mental Health and Biological Changes	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a IDO1 binder may also engage these)

Protein	Name	Similarity
Q9ERD9	—	1.000	Q9ERD9 →
P28776	—	1.000	P28776 →
P0DUR8	—	0.998	P0DUR8 →
A0A2I2F272	—	0.993	A0A2I2F272 →
Q01966	—	0.992	Q01966 →
A0A6G9KIF9	—	0.991	A0A6G9KIF9 →
Q0CG33	—	0.991	Q0CG33 →
A0A823AAW6	—	0.991	A0A823AAW6 →
P47125	—	0.990	P47125 →
F6S9E6	—	0.988	F6S9E6 →
Q8R0V5	—	0.985	Q8R0V5 →
Q9STV0	—	0.984	Q9STV0 →
Q32NQ7	—	0.984	Q32NQ7 →
Q8WUM0	—	0.983	Q8WUM0 →
A1ZB91	—	0.983	A1ZB91 →
B9IJ21	—	0.983	B9IJ21 →
Q9Y3A3	—	0.982	Q9Y3A3 →
Q294E0	—	0.982	Q294E0 →
KDM5D	Lysine-specific demethylase 5D	0.982	landscape →
ELP1	Elongator complex protein 1	0.982	landscape →
M1VV66	—	0.982	M1VV66 →
C5WNV2	—	0.982	C5WNV2 →
A0A1E3B0T7	—	0.982	A0A1E3B0T7 →
Q9VX91	—	0.982	Q9VX91 →
P83372	—	0.982	P83372 →
I1R9A6	—	0.981	I1R9A6 →
A7MBC2	—	0.981	A7MBC2 →
E9Q735	—	0.981	E9Q735 →
KDM5B	Lysine-specific demethylase 5B	0.981	landscape →
A0A3G1DJJ8	—	0.981	A0A3G1DJJ8 →